Degarelix Sustained Release Depot for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer using GnRH agonists and antagonists face challenges such as the 'testosterone surge' phenomenon and safety concerns, including allergic reactions and cardiovascular risks, while also requiring frequent administration to maintain serum testosterone below 0.5 ng/mL.
Innovation Solution
A high-dose, high-concentration formulation of the third-generation GnRH antagonist degarelix, administered as a lyophilisate with an excipient in an aqueous solvent, providing a sustained release depot that maintains therapeutic plasma concentrations for extended periods without the need for monthly injections, thereby reducing side effects and administration frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GnRH agonists are used to treat prostate cancer, then testosterone production is suppressed, but an initial testosterone surge occurs causing symptom worsening
Solution Approach 1:
The patent inverts the mechanism from agonist (stimulation) to antagonist (blockade) to achieve the opposite effect - immediate suppression without surge. The GnRH antagonist composition blocks GnRH receptors from the start, preventing LH surge and subsequent testosterone surge, while maintaining long-term testosterone suppression.
Solution Approach 2:
The patent changes the pharmacological parameter from partial agonism to full antagonism. The composition uses high-dose GnRH antagonist that completely blocks GnRH receptor activation, transforming the dose-response relationship from stimulation at low doses to suppression at all doses, eliminating the flare phenomenon.
2Reliability
If GnRH antagonists are used to avoid testosterone surge, then testosterone production decreases rapidly, but histamine-releasing activity occurs causing allergic reactions
Solution Approach 1:
The patent converts the potentially harmful histamine-releasing property into a beneficial diagnostic tool. The composition includes histamine-releasing GnRH antagonist, and the controlled histamine release is used to confirm proper injection and drug activation, while the overall safety is maintained through proper formulation and dosing.
Solution Approach 2:
The patent introduces an intermediary substance (antihistamine or other protective agents) in the composition to mediate between the GnRH antagonist and the patient's immune system, preventing excessive histamine reactions while allowing the antagonist to function therapeutically.
3Reliability
If frequent injections are administered to maintain therapeutic levels, then testosterone suppression is maintained, but administration burden and side effects increase
Solution Approach 1:
The patent applies preliminary action by administering a high initial loading dose that pre-establishes sufficient drug levels in the system. This loading dose creates a reservoir that maintains therapeutic concentrations for extended periods, eliminating the need for frequent subsequent injections.
Solution Approach 2:
The patent achieves continuous useful action through a formulation designed for sustained release. The composition maintains stable drug levels over extended intervals (3-6 months), providing continuous GnRH receptor blockade and consistent testosterone suppression without interruption or fluctuation.
4Productivity
If high doses are administered to extend treatment interval, then dosing frequency decreases, but injection volume and local side effects increase
Solution Approach 1:
The patent changes the concentration parameter of the formulation to extremely high levels (e.g., 100 mg/mL or higher). This concentration optimization allows delivery of high total doses in small volumes, resolving the contradiction between extended treatment intervals and manageable injection sizes.
Solution Approach 2:
The patent uses composite formulation strategies combining GnRH antagonist with excipients and adjuvants that enhance solubility, stability, and tolerability. This composite approach enables high-dose delivery while minimizing local reactions and maintaining injectability.
Data Source
Figure 1
Figure 2
AI summary
A composition for the treatment of prostate cancer is provided.